Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.
Scott Ripley
Advertisement
Scott Ripley is the general manager, nucleic acid, for Cytiva.
Articles by Scott Ripley
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
3
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
4
Alethio Raises $90 Million to Advance First-in-Class G6B Antibody for Essential Thrombocythemia
5